Drug Search Results
More Filters [+]

Ethosuximide

Alternative Names: ethosuximide, zarontin
Latest Update: 2024-08-07
Latest Update Note: Clinical Trial Update

Product Description

Ethosuximide is used to control absence seizures (petit mal) (a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others). Ethosuximide is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a682327.html)

Mechanisms of Action: T-Type Calcium Channel Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Czech | Denmark | Egypt | France | Germany | Greece | India | Ireland | Italy | Korea | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Poland | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Turkey | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Advicenne Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ethosuximide

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Abdominal Pain|Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IBSET

P2

Active, not recruiting

Abdominal Pain|Irritable Bowel Syndrome

2019-06-10

Recent News Events